Drug news

Syncria (*GSK) is inferior to Victoza in Type 2 Diabetes trial

Read time: 1 mins

Last updated:18th Nov 2011

Published:18th Nov 2011

Source: Pharmawand

Syncria(albiglutide)a once weekly investigational glucagon-like peptide-1 agonist from GlaxoSmithKline failed to show non-inferiority to once daily Victoza (liraglutide) from Novo Nordisk in patients with Type 2 Diabetes in the Phase III HARMONY 7 trial. This is the first of eight Phase III studies of albiglutide to complete in Type 2 Diabetes. Results showed a reduction in HbA1c of 0.78% for patients receiving albiglutide compared to a reduction of 0.99% for liraglutide. Nausea and vomiting rates were lower in patients receiving albiglutide compared to those receiving liraglutide (9.9% versus 29.2% for nausea; 5% versus 9.3% for vomiting).

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approves Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa

UCB, a global biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorization for Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy

1 mins

Drug news

Subcutaneous Ocrevus one-year data from OCARINA II study demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Roche announced data from the Phase III OCARINA II study (S31.006) of Ocrevus (ocrevuslizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection

2 min

Drug news

Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia

Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia

1 min

See all news